In the presented review, some of the main points of the new European recommendations on
the use of double antiplatelet therapy (DAT) and triple antithrombotic therapy in patients with …

This material is the most important excerpt from the clinical guidelines of the European
Cardiological Society (ECS) in 2017 on the use of double antiplatelet therapy (DAT) …

Health professionals are encouraged to take the ESC CPG Guidelines and Focused
Updates developed in collaboration with EACTS fully into account when exercising their …

Platelets play a key role in the pathogenesis of atherothrombosis, involved in both the
development and progression of atherosclerotic heart disease, and the attendant acute …

Atherosclerotic cardiovascular disease is significant part of cardiovascular diseases, the
morbidity and mortality from which is constantly increasing all over the world, including and …

Platelet mediated thrombosis is the primary cause of ischemic event occurrence in patients
with cardiovascular disease. The P2Y12 receptor plays a central role in thrombus …

The content of these European Society of Cardiology (ESC) Guidelines has been published
for personal and educational use only. No commercial use is authorized. No part of the ESC …

The concomitant use of aspirin and an ADP receptor (P2Y12) blocker, also known as dual
antiplatelet therapy (DAPT), has been extensively investigated as a primary and secondary …

In recent years, the problem of P2Y12 inhibitor switching, called escalation and deescalation
of double antiplatelet therapy (DAPT), in patients with acute coronary syndrome (ACS) has …

The role of aspirin and other platelet-active drugs in the treatment and prevention of
atherothrombosis has been reviewed recently by the Sixth American College of Chest …